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Abstract: Uterine leiomyosarcoma (LMS) in some cases may disseminate 
through the abdominal cavity, without extra-abdominal spreading, 
determining a condition of abdominal sarcomatosis, which represents a 
peculiar situation.  Only radical surgical removal offers a chance of 
long-term survival in such cases of LMS. In the present paper, we 
describe an emblematic case of diffuse AS from uterine LMS in a 51-year-
old perimenopausal woman who underwent laparoscopic radical hysterectomy, 
bilateral salpingo-oophorectomy, total pelvic peritonectomy, pelvic 
lymphadenectomy to the mesenteric inferior artery, and omentectomy.  
Then, given the high probability of disease recurrence, the patients 
underwent a close follow up consisting of positron emission tomography 
(PET)/computed tomography (CT) every 3 months and diagnostic (and if 
necessary operative) laparoscopy every 6 months. To date the patient had 
11 laparoscopies; five of them preceded by a PET indicative of the 
presence of disease with high metabolic activity, which was confirmed at 
surgery and each time completely removed laparoscopically with no 
evidence of residual disease. To date, after 5 years from diagnosis the 
patient is alive and continues her follow-up. Our report brings to light 
the ability of laparoscopic surgery to obtain a disease control in case 
of LMS with abdominal dissemination. Moreover, laparoscopic surgery, as 
demonstrated in our case, may have an important role in the close follow-
up of the disease and allow a timely and early radical surgical approach 






Cagliari, 11 April 2016 
Editor-in-Chief 
Journal of Minimally Invasive Gynecology 
 
Dear Editor-in-Chief 
It is a pleasure to submit for consideration the following manuscript entitled “Long-term survival 
in a patient with abdominal sarcomatosis from uterine leyomiosarcoma: role of repeated 
laparoscopic surgery in the treatment and follow-up” for publication in your prestigious journal 
Journal of Minimally Invasive Gynecology as case report. 
 
Uterine leiomyosarcoma in some cases may disseminate through the abdominal cavity, without 
extra-abdominal spreading, determining a peculiar condition of abdominal sarcomatosis.  Only 
radical surgical removal offers a chance of long-term survival in such cases of leyomiosarcoma. 
In the present paper, we describe a case of diffuse abdominal sarcomatosis from uterine 
leyomiosarcoma who underwent laparoscopic radical hysterectomy, bilateral salpingo-
oophorectomy, total pelvic peritonectomy, pelvic lymphadenectomy to the mesenteric inferior 
artery, and omentectomy.  Considering the high risk of relapse, the patients underwent a close 
follow up consisting of positron emission tomography/computed tomography and 
diagnostic/laparoscopy every 6 months. To date the patient had 11 laparoscopies; five of them 
preceded by a positron emission tomography indicative of the presence of disease with high 
metabolic activity, which was confirmed at surgery and each time completely removed 
laparoscopically with no evidence of residual disease. After 5 years from diagnosis the patient is 
alive and continues her follow-up.  
 
Our case supports the ability of laparoscopic surgery to obtain a disease control in case of 
leyomiosarcoma with abdominal dissemination, and demonstrated that laparoscopic surgery may 
have an important role in the close follow-up of the disease and allow a timely and early radical 
surgical approach of relapsed disease. 
 
To our knowledge, our paper is the first that describes such successful use of a repeated 
laparoscopic approach of abdominal sarcomatosis from uterine leyomiosarcoma associated with a 
long-term survival.   
We believe that the findings of this study are relevant to the scope of your journal and will be of 
interest to its readership.  
 
This manuscript has not been published or presented elsewhere in part or in entirety, and is not 
under consideration by any other journal. The patients provided written consent for publication of 
the report. All the authors have approved the manuscript and agree with submission to your 
esteemed journal. There are no conflicts of interest to declare. 
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Uterine leiomyosarcoma (LMS) in some cases may disseminate through the abdominal cavity, 24 
without extra-abdominal spreading, determining a condition of abdominal sarcomatosis, which 25 
represents a peculiar situation.  Only radical surgical removal offers a chance of long-term survival 26 
in such cases of LMS. In the present paper, we describe an emblematic case of diffuse AS from 27 
uterine LMS in a 51-year-old perimenopausal woman who underwent laparoscopic radical 28 
hysterectomy, bilateral salpingo-oophorectomy, total pelvic peritonectomy, pelvic 29 
lymphadenectomy to the mesenteric inferior artery, and omentectomy.  Then, given the high 30 
probability of disease recurrence, the patients underwent a close follow up consisting of positron 31 
emission tomography (PET)/computed tomography (CT) every 3 months and diagnostic (and if 32 
necessary operative) laparoscopy every 6 months. To date the patient had 11 laparoscopies; five of 33 
them preceded by a PET indicative of the presence of disease with high metabolic activity, which 34 
was confirmed at surgery and each time completely removed laparoscopically with no evidence of 35 
residual disease. To date, after 5 years from diagnosis the patient is alive and continues her follow-36 
up. Our report brings to light the ability of laparoscopic surgery to obtain a disease control in case 37 
of LMS with abdominal dissemination. Moreover, laparoscopic surgery, as demonstrated in our 38 
case, may have an important role in the close follow-up of the disease and allow a timely and early 39 
radical surgical approach of relapses before they become extremely large and difficult to remove 40 
radically.  41 
 42 
 43 





The dissemination of soft tissue sarcoma all over the abdominal cavity without extra-abdominal 47 
spread is known as abdominal sarcomatosis (AS), an uncommon disease most often arising from 48 
uterine leiomyosarcoma (LMS) [1]. Although the majority of uterine LMS are confined to the 49 
uterus, many cases involve local spread to peritoneal surfaces and adjacent organs and distant 50 
metastasis [2]. Tumor stage is the strongest prognostic factor for all uterine sarcomas, with a 5-year 51 
survival rate of 50–55% for stage I patients, and 8–12% for patients with more advanced tumors [3]. 52 
The current management of uterine LMS does not take into account individual clinical pathologic 53 
prognostic factors, such as tumor size (>5 or ≤5 cm), mitotic activity (≤10 or >10 mitosis/10 high-54 
power fields [HPFs]), age, and vascular invasion [3]. In view of this evidence, the prognosis of 55 
peritoneal sarcomatosis cannot be well established. Only radical surgical removal offers a chance of 56 
long-term survival in cases of LMS [4]. In this context, AS associated with primary uterine LMS 57 
represents an unusual situation. There are also growing cases involving peritoneal sarcomatosis 58 
from occult uterine LMS following the use of internal morcellation for laparoscopic hysterectomies, 59 
or myomectomy for presumed uterine fibroids [5,6]. The management of AS from uterine LMS is 60 
therefore difficult as optimal radical resection may be complicated by disease spread and frequent 61 
recurrence and very few data are available about a laparoscopic approach. To date, conventional 62 
therapeutic modalities have failed to improve the outcome of patients with uterine LMS associated 63 
with extrapelvic spread. Retrospective analyses [7-10] and phase II studies [11,12] analyzed the 64 
morbidity and mortality of cytoreductive surgery (CRS) and hyperthermic intraperitoneal 65 
chemotherapy perfusion (HIPEC) in the treatment of uterine LMS with abdominal spread. The lack 66 
of effective chemotherapeutic agents coupled with the hematogenous spread of sarcomas means that 67 
the use of CRS-HIPEC remains controversial [1,13]. Furthermore, some authors found no 68 
difference between patients treated with or without HIPEC after complete cytoreduction, suggesting 69 
that resection status is more important for survival than HIPEC use [10,13]. These discordant results 70 
may reflect large variations in the behavior of these tumors, and their best definition is mandatory. 71 
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In this context, we describe one emblematic clinical case of diffuse AS from uterine LMS, with a 72 
long survival obtained through repeated cytoreductive laparoscopic surgeries. The description of 73 
this case may contribute to clarify the central role of surgery, and in particular of a laparoscopic 74 
approach, in the treatment of this disease and implement our knowledge of their biological 75 
heterogeneity, which may have therapeutic implications. 76 
 77 
 78 
Case report 79 
Written informed consent was obtained from the patient for publication of the case report and 80 
accompanying images. The retrospective observational nature of the study did not necessitate the 81 
local institutional ethics committee approval. 82 
Five years ago, a 51-year-old perimenopausal pluriparous (gravida 2 and para 2) Caucasian woman 83 
who was not taking oral contraceptives presented with menometrorrhagia. Physical examination 84 
revealed an enlarged uterus that was thought to be a result of uterine fibromatosis with multiple 85 
myomas. Abdominal ultrasonography (US) confirmed an enlarged uterus deformed by the presence 86 
of probable multiple myomas. Serum CA-125 levels were 75 U/mL (normal range <34 U/ml). For 87 
this reason, we performed laparoscopy to examine the uterus and help determine the most suitable 88 
surgical approach. In reason of the large volume of the uterus, a port was placed above the 89 
umbilicus and a pneumoperitoneum of 14 mmHg was established and maintained throughout the 90 
surgery. Intra-abdominal visualization was achieved using a 10 mm, 0° telescope (Karl Storz, 91 
Tuttlingen, Germany) and three 5-mm trocars were introduced under laparoscopic visualization 92 
through ports in each lower quadrant and in the suprapubic region. Our initial observation showed a 93 
greatly enlarged uterus, deformed by numerous reddish-brown nodules in its anterior and posterior 94 
walls. These neoformations also extended throughout the pelvic peritoneum (Douglas's cavity, 95 
vesicouterine recess, and right pararectal lodge), the great omentum, the mesosigma, the small 96 
intestine mesenterium, and the abdominal peritoneum (Figure 1). Extemporaneous examination 97 
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revealed a mesenchymal neoplasm with signs of atypia compatible with sarcoma. Laparoscopic 98 
surgery was considered possible, and a radical laparoscopic hysterectomy, bilateral salpingo-99 
oophorectomy, total pelvic peritonectomy, pelvic lymphadenectomy to the mesenteric inferior 100 
artery, and omentectomy were performed. The disseminated nodules could be easily resected 101 
because they had not infiltrated the surrounding tissue. Each of the resected nodule fragments and 102 
the lymph nodes were collected in several 10 cm endobags and removed vaginally as well as the 103 
omentum. Uterus was removed in accordance with the bowel bag technique developed by Heaton 104 
for pelvic mass isolation (14). After the radical hysterectomy, with the uterus intact, a bowel bag 105 
was inserted into the abdomen via the vagina, and the uterus was maneuvered into it. The bag 106 
mouth was then brought out through the vagina, and the uterus was morcellated inside the bag to 107 
prevent intra-abdominal contamination. The surgery lasted for 4 hours and it apparently achieved a 108 
complete cytoreduction; and the patient was discharged in good condition after 48 hours. 109 
Pathological examination revealed a uterus weighing 515 grams deformed by various formations 110 
similar to myoma nodes, and 15 irregular nodular neoformations from the abdominal cavity 111 
(diameter ranging from 0.5 to 6 cm). There were also several nodules with a diameter ranging from 112 
0.5 to 3 cm in the omentum. Definitive histopathological examination revealed that all of these 113 
samples were high-grade uterine LMSs with a high mitotic index (43 mitosis/10 HPF), and a Ki-67 114 
of 30%. A LMS was also localized to the right peritubaric space. The adnexa and fallopian tubes 115 
were normal, and 36 resected lymph nodes were free of neoplastic involvement. 116 
After a thorough bibliographic examination, the patient was interviewed to schedule the most 117 
appropriate follow-up and to discuss potential adjuvant therapy. The efficacy of systemic adjuvant 118 
therapy (15) and intraperitoneal hyperthermia is unclear, and there is no evidence for an absolute 119 
benefit of adjuvant therapy compared with surgery alone (16,17,18). Therefore, with the patient’s 120 
agreement, given the high probability of disease recurrence, we decided on a follow up consisting 121 
of positron emission tomography (PET)/computed tomography (CT) every 3 months, which, if 122 
positive, would be accompanied by a diagnostic (and if necessary operative) laparoscopy. A 123 
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diagnostic laparoscopy was planned every 6 months, even in absence of PET positivity, considering 124 
such approach the most appropriate way to obtain the closest monitoring useful for the control of 125 
this insidious disease. At the time of reporting, 11 laparoscopies have been performed; five of them 126 
were preceded by a PET suggesting the presence of disease with high metabolic activity, which was 127 
then confirmed at surgery and each time completely removed laparoscopically with no evidence of 128 
residual disease. Figure 2 show laparoscopic visualization of multiple peritoneal localization of 129 
relapsed LMS. In particular, in the 10
th
 re-intervention the presence of two metastases infiltrating 130 
the small intestine (Figure 3) has made it indispensable to perform the laparoscopic resection of the 131 
interested intestinal tract. The video (supplemental material) shows the laparoscopic removal of the 132 
peritoneal localizations corresponding to the PET/CT images of the multicentric peritoneal nodule 133 
localized at the level of the right common iliac artery (Figure 4).   134 
Surgeries lasted for 90 minutes on average (range 45-120). No bleeding occurred, and the patient 135 
was discharged within 48 hours after each surgery, except after the intestinal resection that required 136 
a discharge after 5 days. The quality of life (QL) assessment after each intervention showed an 137 
excellent performance status. After each surgery, an interview with the patient confirmed the 138 
treatment choice. The patient currently wishes to continue with this approach, and at to date she is 139 




The clinical course of patients with uterine LMS is difficult to predict with the currently available 144 
modified categorical staging system of the International Federation of Gynecology and Obstetrics 145 
(FIGO) [3, 19], especially when an AS is associated with it. AS is defined as the intra-abdominal 146 
dissemination of sarcoma and may be present at initial diagnosis, but is also frequently observed at 147 
recurrence, presumably because of tumor spillage during the initial resection [1]. Recently, a new 148 
category of AS has been observed following uterine morcellation during laparoscopic subtotal 149 
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hysterectomy, laparotomy, or laparoscopic myomectomy for occult LMS [20-22]. This point makes 150 
yet unclear the role of laparoscopic surgery in the management of these tumors. 151 
Indeed, despite the FIGO staging indications, in which AS should be a negative prognostic factor, 152 
the growth of massive intra-abdominal sarcomatoid masses in the absence of distant metastases may 153 
be a potentially favorable prognostic finding in some cases. These clinical pictures illustrate the 154 
lack of a strong relationship between clinical staging and prognosis, and highlight the importance of 155 
basing treatment decisions on the tumor biological characteristics rather than its stage.  156 
The abdominal spread of LMS could indicate either a particularly rapid increase in size facilitated 157 
by the space available in the abdominal cavity rather than a tendency to metastasize to distant sites, 158 
or the development of a multicentric disease, as observed in cases of abdominal benign diffuse 159 
leiomyomatosis [23]. The lack of infiltrating capacity of some of these tumors and the fact that they 160 
can be easily dissected, as showed by us, support this hypothesis, opening in these isolated cases 161 
new perspectives on the use of laparoscopic surgery to safeguard the best QL. Indeed, this evidence 162 
argues also that we are facing with tumors with a peculiar neoplastic behavior. Therefore, more 163 
complex post-surgical staging systems that can facilitate the best therapeutic choice are needed. In 164 
addition to stage, other prognostic factors in uterine LMS should include age, grade, tumor size, 165 
mitotic rate, DNA ploidy, and menopausal status, none of which are incorporated into the FIGO 166 
staging system [24]. Indeed, the American Joint Committee on Cancer uses a separate staging 167 
system specifically for soft tissue sarcomas that, among other variables, includes tumor size and 168 
grade [25]. Neither of these two staging systems assesses the tumor size and local spread in addition 169 
to their infiltrating and distant metastatic ability. This is important because, as surgery is the 170 
mainstay therapy for these tumors, the best definition of the disease would help to avoid to selected 171 
patients adjuvant chemotherapy, which has uncertain efficacy and is associated with adverse effects 172 
that can severely affect the patient’s QL.  173 
Supporting this observation, another point to be discussed is the role of the most appropriate 174 
imaging technique able to identify the recurrence in order to plan an early and more effective 175 
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surgical approach. In this context some studies have demonstrated that the PET/CT is a highly 176 
sensitive and specific modality for detecting recurrence in post-therapy patients with LMS (26,27). 177 
Moreover, the peritoneal metastases, especially those localized between the short bowel intestinal 178 
loops, cannot be easily identified with CT.  Vice versa, PET/CT can identify the metabolic activity 179 
of such lesions and therefore give information about their presence.   180 
In conclusion, only recently, evidence support also a role of laparoscopic surgery for the treatment 181 
of early stage uterine sarcomas (28). A laparoscopic approach as described in the present case can 182 
be pursued only in centers with great expertise with laparoscopic hysterectomy (29).  183 
A new approach along these lines could offer an extended role for laparoscopy in the management 184 
of abdominal LMS, as demonstrated by our case, respecting the best patient’s QL. This, in turn, 185 
would allow a timely and early surgical approach before they become extremely large.  Further 186 
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Figure legend 271 
Figure 1. Laparoscpic visualization of the uterus and multiple peritoneal pelvic metastatic 272 
localizations of leyomiosarcoma at diagnosis.  273 
Figure 2. Laparoscopic visualization of the multiple peritoneal nodules of relapsed 274 
leyomiosarcoma. Black arrows indicate the malignant lesions extended throughout the peritoneum 275 
of the pelvis and abdominal wall. 276 
Figure 3. A laparoscopic view of the large relapsed nodule of leyomiosarcoma localized in the 277 
small intestine wall. 278 
Figure 4. Triaxial PET/CT imaging of the multicentric peritoneal nodules from relapsed 279 
leyomiosarcoma localized above the right common iliac artery. 280 
 281 
Supplemental material: Video showing the surgical laparoscopic removal of the multicentric 282 
peritoneal nodule of relapsed leyomiosarcoma localized above the right common iliac artery. 283 
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